Vast majority of ophthalmologists treating uveal melanoma use molecular testing to guide patient care: vision-research.eu

Castle Biosciences Inc. has announced the publication of study results that assess current clinical practices for uveal melanoma (UM) and demonstrate the impact of molecular prognostic testing on patient management.

The paper, "Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses," was published in the peer-reviewed journal Clinical Ophthalmology.

vision-research.eu - The Gateway to European Vision Research

Vast majority of ophthalmologists treating uveal melanoma use molecular testing to guide patient care

Related Links